Enzymes for Companion Diagnostics (CDx)
Companion diagnostics (CDx) represent a cornerstone of precision medicine, providing essential information that guides therapeutic decisions based on a patient's molecular profile. These diagnostics identify whether a patient is likely to benefit from a specific drug, determine optimal dosage, or predict adverse reactions, thereby enhancing treatment efficacy and safety.
Within this paradigm, enzymes play a critical role as both biocatalytic reagents and signal-generation components in diagnostic assays. From sample preparation to signal amplification, enzyme-driven reactions underpin the performance, sensitivity, and reliability of companion diagnostic platforms.
At Creative Enzymes, we deliver a diverse range of diagnostic-grade enzymes tailored for use in CDx assay development, validation, and manufacturing. Our enzymes meet stringent quality and regulatory requirements, providing consistent batch-to-batch activity, high purity, and superior stability for both in vitro and ex vivo applications.
Enzymes serve as essential tools in every analytical layer of CDx assay design. Their ability to catalyze reactions with high substrate specificity and reproducibility makes them invaluable across multiple diagnostic platforms, including:
Through precise enzyme selection and engineering, companion diagnostics achieve high analytical sensitivity, low background interference, and robust assay reproducibility, all essential for regulatory approval and clinical utility.
The majority of companion diagnostics rely on nucleic acid amplification-based assays to identify mutations, translocations, or polymorphisms linked to drug response. Enzymes such as Taq DNA polymerase, reverse transcriptase, and restriction endonucleases are fundamental to PCR and sequencing workflows.
Creative Enzymes provides high-fidelity polymerases and RNase-free reverse transcriptases optimized for clinical-grade sensitivity, enabling reliable detection of low-abundance alleles in oncogenes such as EGFR, BRAF, or KRAS.
Many CDx tests, particularly those supporting targeted therapies or immunotherapies, measure protein-level biomarkers. Enzymes such as horseradish peroxidase (HRP) and alkaline phosphatase (ALP) act as signal amplifiers in immunohistochemistry (IHC), ELISA, and chemiluminescent assays, ensuring precise quantitation and visualization of biomarker expression.
Creative Enzymes offers enzyme-antibody conjugation services and custom HRP/ALP formulations with enhanced signal-to-noise ratios and extended stability for automated staining platforms.
With the rise of next-generation sequencing (NGS)-based companion diagnostics, enzymes have become central to nucleic acid library preparation and molecular tagging. Our proofreading DNA polymerases, ligases, and endonucleases support high-throughput genomic applications requiring extreme accuracy and uniform coverage.
We also supply nick translation and DNA repair enzymes for precise fragment processing in hybrid capture-based CDx workflows.
The expansion of decentralized and point-of-care companion diagnostics has accelerated the adoption of miniaturized enzymatic detection systems. Enzymes with high catalytic turnover and temperature tolerance enable compact assay formats such as microfluidic chips, biosensors, and electrochemical detection arrays.
Creative Enzymes develops enzyme variants suitable for integration into lab-on-chip devices and POCT (Point-of-Care Testing) platforms—critical for real-time treatment decision-making in oncology and infectious disease management.
Companion diagnostics are also applied in evaluating drug metabolism pathways, particularly in pharmacogenomics. Enzymes such as cytochrome P450 oxidases, dehydrogenases, and transferases serve as biological correlates for drug clearance and metabolic response.
Creative Enzymes supplies recombinant metabolic enzymes for pre-clinical biomarker validation and enzyme activity-based companion assays, bridging pharmaceutical discovery and patient stratification.
Creative Enzymes integrates enzyme production, engineering, QC/QA, and custom conjugation under one unified platform. Every enzyme is validated for purity, activity, stability, endotoxin level, and reagent compatibility, accompanied by a detailed Certificate of Analysis (CoA).
Our technical team provides custom assay development support for CDx manufacturers, including enzyme formulation optimization, buffer compatibility assessment, and analytical method validation for precision diagnostic workflows.
Q1. What distinguishes enzymes used in companion diagnostics from research-grade reagents?
Q2. Are your enzymes suitable for regulatory submissions (e.g., FDA, CE-IVD)?
Q3. Do you provide enzyme conjugation or assay customization for specific drug–biomarker pairs?
Q4. Can you supply bulk enzymes for commercial IVD production?
Q5. What enzyme stabilization options are offered for CDx kit integration?
| Catalog | Product Name | EC No. | CAS No. | Source | Price |
|---|
